#### 1 EPCs-derived conditioned medium mitigates chronic cerebral ischemic injury

#### 2 through the MIF-activated AKT pathway

3

Ya-Wen Cheng<sup>1</sup>, Ling-Yu Yang<sup>1</sup>, Yi-Tzu Chen<sup>1,2</sup>, Sheng-Che Chou<sup>1,2</sup>, Kuo-Wei 4 Chen<sup>1,2</sup>, Yi-Hsing Chen<sup>1,2</sup>, Chuan-Rou Deng<sup>1</sup>, I-Chin Chen<sup>1</sup>, Wan-Ju Chou<sup>1,2</sup>, 5 Chen-Chih Chang<sup>3</sup>, Yong-Ren Chen<sup>4</sup>, Hsiao-Lin Hwa<sup>5</sup>, Kuo-Chuan Wang<sup>1\*</sup>, and 6 Meng-Fai Kuo<sup>1\*</sup> 7

8

#### Short title: The role of MIF in the EPC-CM in CCI 9

10

#### Affiliations of authors: 11

- 12 Division of Neurosurgery, Department of Surgery, National Taiwan University 1 Hospital, Taipei, Taiwan 13
- 14 2 Graduate Institute of Clinical Medicine, National Taiwan University College 15 of Medicine, Taipei, Taiwan
- Department of Internal Medicine, National Taiwan University Hospital, College of 16 3
- 17 Medicine, National Taiwan University, Taipei, Taiwan
- 4 Division of Neurosurgery, Department of Surgery, National Taiwan University 18
- Hospital Jinshan branch, Taipei, Taiwan 19
- 20 Department of Obstetrics and Gynecology, National Taiwan University Hospital, 5
- 21 Taipei, Taiwan

- <sup>\*</sup>Corresponding authors: 23
- 24 Meng-Fai Kuo, mfkenator@gmail.com
- 25 Division of Neurosurgery, Department of Surgery, 7 Chung Shan South Road, Taipei
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 100, TalWan

- 1 TEL: +886-2-23123456 EXT. 271837
- 2 FAX: +886-2-23934358
- 3 and
- 4 Kuo-Chuan Wang, <u>wang081466@yahoo.com.tw</u>
- 5 Division of Neurosurgery, Department of Surgery, National Taiwan University
- 6 Hospital, No.7, Chung Shan South Road, Taipei 100, Taiwan
- 7 TEL: +886932198500
- 8 FAX: +886-2-23934358
- 9
- 10

#### 1 Abstract

**Background** Chronic cerebral ischemia (CCI) is considered as a prelude to neurodegeneration. Endothelial progenitor cells (EPCs) have been implicated in revascularization and vascular repair in cerebral ischemic diseases. Due to the safety concern and the low survival rate of the transplanted cells, interest has shifted toward the paracrine effect of EPCs. Here, we investigate the effects of EPC-derived conditioned medium (EPC-CM) on the vascular and functional impairments in a rodent model of CCI and the mechanism via which the EPC-CM involves.

Methods Bilateral internal carotid artery ligation (BICAL) was performed in rats to 9 10 induce cerebral ischemia. EPC-CM was intracisternally injected 1 week after BICAL. The changes of the microvasculature and behavior were examined 3 weeks after 11 12 BICAL. The EPC-CM was analyzed by cytokine array for the factors that involved in 13 angiogenesis. The therapeutic effects and mechanism of the candidate factor was 14 validated with oxygen-glucose deprivation-injured endothelial cells and EPCs in vitro. 15 **Results** EPC-CM significantly improved the vascular, motor and cognitive 16 impairments of the BICAL rats. Macrophage migration inhibitory factor (MIF) was 17 identified as a key factor in EPC-CM involved in angiogenesis and anti-senescence. 18 Furthermore, recombinant MIF protein mirrored the effects of EPC-CM on EPCs and 19 ECs. These therapeutic effects were decreased by the co-treatment with EPC-CM and 20 MIF-specific antibody both in vivo and in vitro. MIF operates through multiple 21 pathways, including the AKT pathway, which plays a crucial role in cellular 22 homeostasis. Inhibiting the AKT pathway diminished the protective effect of MIF in 23 the CCI model.

Conclusions We demonstrated that EPC-CM protected the chronic ischemic rat brain
from ischemic injury and promoted functional recovery in rats through MIF-mediated
AKT pathway, which indicated that EPC-CM may serve as an alternative potential

- 1 therapy in chronic cerebral ischemia.
- 2

#### 3 Key words:

- 4 Endothelial progenitor cell-derived conditioned medium, cerebral ischemia,
- 5 macrophage migration inhibitory factor, AKT pathway
- 6

#### 7 Non-standard Abbreviations and Acronyms

- 8 CCI: chronic cerebral ischemia
- 9 BICAL: bilateral internal carotid artery ligation
- 10 EPC-CM: endothelial progenitor cell-derived conditioned medium
- 11 MIF: macrophage migration inhibitory factor
- 12 OGD: oxygen-glucose deprivation
- **13** ECs: Endothelial cells
- 14 HUVEC: human umbilical vein endothelial cell
- 15 SA- $\beta$ -gal: senescence associated  $\beta$ -galactosidase
- 16 DAPI: 4',6-diamidino-2-phenylindole
- 17 NOR: novel object recognition

18

#### 1 Introduction

Chronic cerebral ischemia (CCI) results from inadequate blood flow to the brain.
The decrease in cerebral perfusion induces brain tissue damage, cognitive impairment,
and neurodegeneration, eventually causing ischemic stroke and Alzheimer's disease<sup>1-4</sup>.
Addressing this issue and finding ways to support neuron survival and neurological
recovery is crucial due to the global impact of cerebral ischemic disease.

7 Endothelial progenitor cells (EPCs) are circulating cells capable of becoming 8 endothelial cells for vascular regeneration. They play a vital role in repairing damaged blood vessels in ischemic disease<sup>5-7</sup>. EPCs secrete a wide range of growth factors, 9 chemokines, cytokines, and extracellular vesicles that contribute to angiogenesis, 10 reconstruct the vascular microenvironment<sup>8-10</sup>, and improved the recovery of 11 neurological function after cerebral injury<sup>11, 12</sup>. Although cell-based therapy has 12 13 shown promising effects in preclinical models after stroke, the administration of EPCs may have adverse side effects. Therefore, conditioned medium (CM) collected from 14 EPCs has emerged as an alternative potential cell-free therapeutic agent $^{13-15}$ . 15

Our previous study demonstrated that the administration of EPCs combined with 16 indirect revascularization protected against chronic cerebral ischemic injury<sup>16</sup>, but the 17 therapeutic effects of EPC-secreted factors have not been investigated in preclinical 18 19 models of CCI. We investigated the therapeutic effect of secreted factors from EPCs 20 on CCI and the molecular mechanism involved in the neurorepair process. Many 21 proteins and cytokines are secreted from EPCs, and we focused on macrophage migration inhibitory factor (MIF) among the secreted factors<sup>17</sup>. MIF is a pleiotropic 22 protein that has the characteristics of a cytokine that is secreted by different types of 23 cell, including neural stem/progenitor cells and EPCs<sup>18, 19</sup>. In addition to being 24 recognized as a regulator of the immune response, increased studies have 25 demonstrated that MIF is involved in a variety of signaling pathways important for 26

1 the maintenance of cellular homeostasis, such as promoting cellular survival,

2 angiogenesis, and anti-senescence  $^{18, 20}$ .

In this study, we used a bilateral internal carotid artery ligation (BICAL) rat model as the CCI animal model and an *in vitro* cell-based system to determine whether EPC-CM promotes the recovery of brain tissue injury and vascular repair and further investigated the molecular mechanism involved in this process. The results demonstrated that EPC-CM can ameliorate ischemic injury and promote vascular repair in the brain via MIF-mediated AKT pathway activation.

#### 1 Methods

-	
3	This study included the performance of animal experiments and obtaining EPCs from
4	fresh human umbilical cord blood, and was approved by the Institutional Animal Care
5	and Use Committee of National Taiwan University (Approval no. IACUC-20180430)
6	and the Institutional Review Board of National Taiwan University Hospital (Approval
7	no. IRB-201204074RIC and IRB-202012174RIND), Taipei, Taiwan. All surgical
8	procedures were performed according to the Guide for the Care and Use of
9	Laboratory Animals (issued by the National Institutes of Health) and approved by the
10	Committee.
11	
12	Detailed information of the materials and methods
13	The detailed information of the materials and methods of the in vivo and in vitro
14	studies were provided in the Supplementary Materials and Methods.
15	
16	Animal model of chronic cerebral ischemia: bilateral internal carotid artery
17	ligation (BICAL)
18	Male Wistar rats (200-250 g, body weight) were randomly assigned to the BICAL
19	surgery or treatment groups, and littermate control. The BICAL procedure was
20	performed as described previously <sup>16</sup> .
21	
22	Treatment algorithm
23	The sham and BICAL animals received an injection of 40 $\mu$ l vehicle, i.e, 0.9% normal
24	saline into the cisterna magna, while the treatment groups received intracisternal
25	injection of EPC-CM (40 $\mu l)$ or EPC-CM+ MIF Ab (anti-MIF antibody 2 $\mu g$ mixed
26	with 40 $\mu$ l EPC-CM) 24 hrs after BICAL procedure. The body temperature was 7

1 maintained stable for 3 hrs after the treatment with vehicle, EPC-CM, or EPC-CM+

2 MIF Ab.

3

#### 4 Microcirculation assessment

5 Study and quantification of brain surface microcirculation 3 weeks after BICAL
6 surgery was performed as described previously<sup>16</sup>.

7

#### 8 Microvasculature density

9 The microvascular densities were measured three weeks after BICAL surgery. The 10 capillary microcirculation on the rat brain surface was evaluated using a CAM1 11 capillary anemometer (KK Technology, UK) with a high-resolution (752 x 582 pixels) 12 monochrome charge-coupled device (CCD) video camera. The microvasculature 13 density was calculated using the De Backer's score<sup>21</sup>.

14

#### **15 Rotarod performance test**

The rotarod test was performed as previously described<sup>21</sup>. Rats were pre-trained for three days at a speed of 4 rpm, 3 sessions per day for 5 min on the instrument (Panlab Rota Rod, Harvard Apparatus) before BICAL surgery. Three weeks after BICAL surgery, the rats were placed on the instrument and the latency to fall was measured under continuous acceleration (4 to 40 rpm for 600 secs) by observers blinded to group assignment.

22

#### 23 Novel Object Recognition (NOR) test

We conducted the NOR test to assess short-term recognition memory that originally
described by Ennaceur and Delacour procedure<sup>22</sup>.

#### **1** Statistical analysis

Data collection and analysis were carried out by investigators who were blinded to the
experimental conditions. Data are expressed as the mean ± standard deviation (SD).
Data was analyzed for normality by the Shapiro–Wilk normality test. One-way
analysis of variance (ANOVA) followed by a Post HocTest (Tukey's multiple
comparisons test) was used for normally distributed data. Bar graphs and statistical
analysis were performed by GraphPad Prism 7.0 software (GraphPad Software, USA).
A P-value of <0.05 was considered a statistically significant difference.</li>

#### Results 1

#### 2 EPC-CM treatment rescues the vascular impairment induced by BICAL

3 The microcirculation on the cortical surface, including the artery (a) and vein (v), 4 showed significantly sparse in BICAL rats as compared with control rats. In addition, 5 arterioles (a) on the brain surface exhibited markedly diffuse vasoconstriction in 6 BICAL rats, resulting in ischemia (Figure 1A, middle panel). Notably, impairment of 7 microvasculature and arterioles were rescued by treatment with EPC-CM (Figure 1A, 8 right panel). As microvascular networks supply oxygen to brain tissue, we detected 9 the microvasculature density, regional blood flow, and partial pressure of brain tissue 10 oxygen (PtO<sub>2</sub>) in BICAL rats treated with/without EPC-CM. These measures, which had notably declined in the BICAL rats, were restored with EPC-CM treatment, 11 12 indicating an improvement in cerebral perfusion (Figure 1B-D). Taken together, these data suggested that EPC-CM rescues the vascular impairment induced by BICAL. 13

14

#### 15 EPC-CM and MIF protein promote angiogenesis in OGD-treated endothelial 16 cells (ECs)

17 To investigate the critical factor in EPC-CM that is responsible for mediating vascular and neural repairs in BICAL rats, cytokine array of EPC-CM was performed that 18 19 showed macrophage migration inhibitory factor (MIF) among the secreted factors of EPC-CM as a putative candidate for promoting angiogenesis and cell survival<sup>23, 24</sup> 20 21 (Figure 2A, Table S1). Therefore, we tested the role of MIF in ECs by using human 22 umbilical vein endothelial cells (HUVECs) treated with/without EPC-CM or MIF 23 recombinant protein (rMIF) subjected to oxygen-glucose deprivation (OGD) to mimic chronic ischemic conditions. We investigated cell survival in HUVECs treated with 24 25 OGD for 24 hrs and found no significant differences between each group, indicating that the condition did not cause significant cell death (Figure 2B). Next, we validated 26

the angiogenesis function of the ECs by performing tube formation and migration assays. As shown in Figure 2C and 2D, compared to normoxia, OGD treatment significantly inhibited tube formation and cell migration. Interestingly, OGD cells treated with EPC-CM or rMIF showed similar increases in tube formation and cell migration (Figure 2C-2D). The data indicated that both EPC-CM and rMIF increase angiogenesis in the *in vitro* chronic ischemic model.

7

# 8 EPC-CM and MIF protein promote anti-senescence ability in ECs and EPCs *in*9 *vitro*

Senescence is associated with neurodegeneration diseases<sup>25</sup>. Senescent EPCs showed 10 11 decreased proliferation and angiogenesis. Therefore, we determined the 12 anti-senescence effect mediated by EPC-CM or rMIF on EPCs and ECs. Young EPCs or ECs were treated with prolonged hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to induce senescence, 13 followed by treatment with EPC-CM (20%) or rMIF (100 ng/ml). As shown in Figure 14 15 3, H<sub>2</sub>O<sub>2</sub> treatment significantly increased the number of senescent cells compared with that in the control (Figure 3, lane 1 vs. lane 2 in the bar graphs). Notably, 16 17 EPC-CM or rMIF treatment reversed the senescence level in EPCs (Figure 3A) and 18 ECs (Figure 3B). These data indicated that EPC-CM or MIF may promote 19 angiogenesis by rejuvenating senescent EPCs or ECs after ischemic damage.

20

# 21 Transduction of EPCs with lenti-hMIF increases cell angiogenesis and 22 anti-senescence *in vitro*

To further confirm the role of MIF in angiogenesis and anti-senescence, we generated the human MIF-expressing EPCs by lentivirus, and validated the hMIF expression by Western blotting (Figure S1A). Angiogenesis and the anti-senescence capacity were tested in the hMIF-expressing EPCs compared with the lentiviral vector-transduced

EPCs (Mock). As shown in Figure S1B and S1C, hMIF-expressing EPCs rescued tube formation and migration with OGD treatment as compared with OGD-treated cells infected with lentiviral vector. In addition, hMIF-expressing EPCs also restored the senescence level after  $H_2O_2$  induction (Figure S1D), consistent with Figure 3. These data proved that MIF is an important protein that regulates angiogenesis and anti-senescence in EPCs.

7

## 8 MIF is an important factor in EPC-CM that promotes angiogenesis and brain 9 functional recovery in chronic ischemic events

To validate the role of MIF in the recovery of neurological function regulated by EPC-CM, we used anti-MIF antibody (Ab) to specifically block the effect of MIF in EPC-CM. While EPC-CM treatment significantly restored the tube formation (Figure 4A) and migration capacity (Figure 4B) inhibited by OGD treatment (Figure 4, lane 2 vs. lane 3 in the bar charts), the effect of EPC-CM was reduced by MIF Ab treatment (Figure 4, lane 3 vs. lane 4 in the bar charts). The data indicated that MIF is the key factor in EPC-CM that promotes angiogenesis and anti-senescence capacity.

17 To further study the effect of MIF in the CCI animal model. Wistar rats were 18 randomly separated into four groups (control, BICAL, BICAL+EPC-CM, BICAL+EPC-CM+MIF Ab) and underwent BICAL surgery followed by EPC-CM or 19 20 EPC-CM+MIF Ab treatment as previously described (Figure 5A). The blood flow and 21 PtO<sub>2</sub> were examined for the repair of the microcirculation. According to Figure 5B 22 and 5C, EPC-CM showed a great vascular repair effect on blood flow and PtO<sub>2</sub>, 23 which was significantly repressed by MIF-Ab co-treatment, indicating that MIF plays 24 an important role in EPC-CM-mediated vascular repair. Furthermore, we investigated 25 the effects on the motor and cognition functions of BICAL rats treated with/without 26 EPC-CM or EPC-CM+MIF Ab with rotarod test and the novel object recognition

(NOR) assay, respectively. EPC-CM treatment reduced both motor coordination
 deficits and recognition memory impairment after BICAL, which were abolished by
 MIF Ab co-treatment (Figure 5D-E). These data indicated that EPC-CM is a potential
 cell-free therapy for CCI and MIF is the key factor in EPC-CM that promotes vascular
 repair.

6

#### 7 MIF promotes angiogenesis and anti-senescence by activating the AKT pathway

8 Having established the role of MIF in promoting angiogenesis and anti-senescence by in vitro system, we investigated the underlying mechanism. Previous studies 9 10 demonstrated that MIF increased angiogenesis and anti-senescence by mediating the 11 phosphatidylinositol 3' -kinase (PI3K) /AKT signaling pathway and mitogen-activated protein kinase (MAPK)<sup>23, 26</sup>. Therefore, we investigated the regulation of MIF or 12 13 EPC-CM on ERK1/2 and AKT activity in EPCs. EPCs treated with rMIF or EPC-CM both showed significant increases in ERK1/2 and AKT phosphorylation, consistent 14 15 with previous studies (Figure 6A). Next, we detected ERK1/2 and AKT activity with/without EPC-CM or rMIF treatment under OGD conditions. We found that 16 17 EPC-CM or rMIF treatment increased the AKT activity inhibited by OGD in ECs and 18 EPCs but not the ERK1/2 pathway (Figure 6B). The data indicated that AKT is the 19 critical pathway regulated by MIF to promote angiogenesis and anti-senescence. To 20 validate this hypothesis, we used a PI3K/AKT inhibitor, LY294002, to inhibit AKT 21 activity, and the inhibitory efficacy was confirmed by Western blotting (Figure 6B, 22 lane 5). As shown in Figure 6C and 6D, the tube formation and cell migration 23 promoted by rMIF treatment was abolished by AKT inhibitor co-treatment. In 24 addition, the anti-senescence effect mediated by rMIF was repressed by the AKT 25 inhibitor (Figure 6E). Taken together, these data suggested that activation of AKT plays an important role in MIF-mediated neurologic repair by increasing angiogenesis 26

1 and anti-senescence in CCI.

### 1 **Discussion**

2 Chronic cerebral ischemia (CCI) is highly correlated with neurodegenerative 3 diseases and increases the mortality and disability rate in aging patients. Unfortunately, effective therapies for CCI are limited. In this study, we showed that conditioned 4 5 medium derived from EPCs enhanced microcirculation, and cognitive and motor functions of CCI animals. We further identified MIF, a pleiotropic cytokine, as a 6 7 critical factor in EPC-CM that exhibits angiogenesis and anti-senescence activities, 8 facilitating tissue recovery in both in vivo and in vitro stusies. Mechanistically, EPC-CM promoted angiogenesis and anti-senescence in EPCs and ECs through 9 10 MIF-mediated AKT activation. Overall, we demonstrated the therapeutic actions of 11 EPC-CM in vascular and brain functional improvement in experimental CCI model.

12 Vascular repair is critical for cerebral protection after ischemic insults. EPCs, as the precursor cells of ECs, play a pivotal role in repairing injured vessels and 13 participate in endothelial regeneration<sup>27, 28</sup>. Despite their attractiveness as a 14 15 therapeutic approach for ischemic diseases, challenges such as immunogenicity, tumorigenic potential, and formation of emboli limit the clinical application of EPC 16 transplantation<sup>29</sup>. The detailed mechanism by which EPCs contribute to vascular 17 repair is still unclear. There are two mechanisms by which EPCs promote vascular 18 19 repair. One is that EPCs migrate to the ischemic region and differentiate into ECs to 20 repair damaged vessels. The other is that the recruited EPCs secrete protective paracrine factors to promote vascular repair $^{30}$ . The latter mechanism, particularly 21 22 relevant for its stability, safety, and low immunogenicity, has gained prominence. 23 Evidence supports that EPC-mediated vascular repair via paracrine signaling, activating resident ECs, is more critical than direct differentiation into damaged 24 vessels<sup>13, 31, 32</sup>. In current study, we demonstrated that the administration of EPC-CM 25 facilitates vascular repair after BICAL. Furthermore, by analyzing the paracrine 26

factors of EPCs with a cytokine array, we focused on the role of MIF in
 EPC-CM-mediated promotion of angiogenesis and cell survival after BICAL.

3 We used the BICAL model, a CCI animal model, to investigate the therapeutic effects of EPC-CM. The cerebral ischemia induced by BICAL was validated by 4 5 microcirculation changes, including decrease of vascular density, regional blood flow, 6 and PbtO<sub>2</sub>. The microcirculation changes were significantly ameliorated by the 7 administration of EPC-CM. Notably, EPC-CM treatment also rescued the impaired 8 motor and recognition functions in BICAL rats that suggested the role of EPC-CM in neuronal protection after ischemic insults. The EPC-CM cytokine profile highlighted 9 10 MIF as a key factor in promoting vascular and neuronal repairs. Intriguingly, 11 MIF-specific antibody treatment inhibited the therapeutic effects mediated by 12 EPC-CM, reinforcing the pivotal role of MIF in vascular repair and neuronal 13 recovery.

14 MIF was first identified as an inflammatory cytokine and is now recognized as a 15 protective factor that involves in diverse physiological processes, including angiogenesis, antioxidant activity, and cell survival<sup>19, 33</sup>. Many studies have 16 demonstrated that MIF participates in the recovery of ischemic injuries<sup>34-37</sup>. MIF can 17 suppress oxidative stress by its redox activity or inhibit the transcription of P53 to 18 decrease cell apoptosis and senescence. MIF also promotes angiogenesis<sup>38-40</sup>. 19 However, other studies have reported that MIF aggravates ischemic damage<sup>41, 42</sup>. 20 Inácio *et al.* found a smaller infarct size 7 days after stroke in MIF-knockout mice<sup>42</sup>. 21 22 These studies pointed out that MIF has different roles during ischemia, either 23 promoting neuronal recovery by inhibiting cell death or being harmful to neurons by 24 increasing the inflammatory response in ischemic region, and the mechanism 25 underlying the different roles of MIF is still unclear. One possibility is that higher expression of MIF may activate broad signaling pathways and inflammation. In the 26

1 rodent permanent middle cerebral artery occlusion (MCAO) models, MIF showed 2 detrimental effects, which increased the permeability of blood brain barrier and the infarction volume with 3.3  $\mu$ g/kg administration in Liu's study<sup>43</sup>, whereas 0.9 ng MIF 3 injected into mice via the ventricle (final 120 ng/ml concentration) promoted 4 neurological recovery<sup>34</sup>. The MIF concentration in EPC-CM was 12 ng/ml, and 5 treatment with 40 µl EPC-CM in BICAL rats showed significant protective effects in 6 7 our study, which is consistent with the low dose of MIF administered in the ischemic 8 stroke model $^{34}$ .

Furthermore, we showed the therapeutic effects mediated by MIF by increasing 9 10 angiogenesis and anti-senescence in EPCs and ECs in the in vitro CCI model. 11 Secreted MIF activates multiple cellular signaling pathways by binding to the cellular receptor CD74<sup>44</sup>. The interaction of MIF with CD74, triggers various signaling 12 13 pathways, including the MAPK and PI3K/AKT pathways, which are crucial for angiogenesis and anti-senescence<sup>23, 45</sup>. In addition, MIF can bind to other receptors, 14 CXCR2 and CXCR4, to regulate cell proliferation, survival, angiogenesis, and 15 chemotaxis<sup>46, 47</sup>. Here, we demonstrated that MIF promotes angiogenesis via 16 17 activation of the PI3K/AKT pathway to increase tube formation, cell migration, and anti-senescence. 18

Cerebral small vessel impairment is related to various diseases, especially 19 cognitive dysfunction, vascular dementia, and stroke in elderly patients<sup>48</sup>. This study 20 21 demonstrated the therapeutic effect of EPC-CM in animal model of CCI. Notably, in prior research, CM was administered for multiple times<sup>9, 11</sup>, while here, EPC-CM was 22 23 delivered once, 7 days following BICAL surgery, yet still exhibited a substantial effect. This indicates that the EPC-CM used in our study had long-term effects on 24 EPC-mediated reendothelialization and neovascularization, which might be due to 25 EPC chemotaxis to the ischemic region mediated by MIF<sup>16, 49</sup>. An intriguing avenue 26

for exploration is whether the vascular repair facilitated by EPC-CM could extend to
 various ischemic diseases. Further investigation is needed to elucidate the detailed
 mechanism of EPC-CM and MIF after ischemic events.

## 4 Conclusion

In conclusion, our study in an animal model highlighted the therapeutic potential of EPC-CM for CCI. The pivotal role of MIF in angiogenesis and anti-senescence through the activation of the PI3K/AKT pathway provides mechanistic insights into the neuroprotective effects of EPC-CM. These findings hold promise for developing novel therapies for cerebral ischemic diseases.

#### 1 Data Availability

2 The data that support the findings of this study are available from the corresponding3 authors upon reasonable request.

4

#### 5 Acknowledgments

6 We thank the Animal Core Facility, Department of Medical Research, the Second and 7 the Third Core Labs, Department of Medical Research, National Taiwan University 8 Hospital for technical support during the study. YWC and KCW designed research, 9 data interpretation, writing and revising of the manuscript; YWC performed in vitro 10 experiments, acquired and analysis of the data; LYY, CRD, SCC, KWC, and YHC performed animal experiments. ICC and WJC contributed to Western blotting. YTC, 11 12 YRC, HLH and CCC contributed to EPCs preparation. KCW and MFK contributed to 13 overall direction, funding acquisition and critical revision of the manuscript.

- 14
- 15

#### 16 Sources of Funding

17 This work was supported by the Ministry of Science and Technology, Taiwan

18 (MOST 108-2314-B-002-086, 109-2314-B-002-124-, 110-2314-B-002-160-MY2, and

19 112-2314-B-002-240- to Dr. MF Kuo, and 108-2314-B-002-085-MY2,

- 20 110-2314-B-002-159, and 111-2314-B-002-254-MY2 to Dr. KC Wang).
- 21

### 22 Disclosures

23 The authors declare no competing interests.

24

25

### 1 **References**

2	1.	Cechetti F, Pagnussat AS, Worm PV, Elsner VR, Ben J, da Costa MS, et al.
3		Chronic brain hypoperfusion causes early glial activation and neuronal death, and
4		subsequent long-term memory impairment. Brain Res Bull. 2012;87:109-116
5	2.	Ciacciarelli A, Sette G, Giubilei F, Orzi F. Chronic cerebral hypoperfusion: An
6		undefined, relevant entity. J Clin Neurosci. 2020;73:8-12
7	3.	Jing Z, Shi CZ, Zhu LH, Xiang YH, Chen PH, Xiong ZL, et al. Chronic cerebral
8		hypoperfusion induces vascular plasticity and hemodynamics but also neuronal
9		degeneration and cognitive impairment. J Cerebr Blood F Met.
10		2015;35:1249-1259
11	4.	Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's
12		disease. Ann Nucl Med. 2001;15:85-92
13	5.	Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating
14		endothelial progenitor cells and cardiovascular outcomes. New Engl J Med.
15		2005;353:999-1007
16	6.	Zhao YH, Yuan B, Chen J, Feng DH, Zhao B, Qin C, et al. Endothelial progenitor
17		cells: Therapeutic perspective for ischemic stroke. Cns Neurosci Ther.
18		2013;19:67-75
19	7.	Kukumberg M, Zaw AM, Wong DHC, Toh CM, Chan BPL, Seet RCS, et al.
20		Characterization and functional assessment of endothelial progenitor cells in
21		ischemic stroke patients. Stem Cell Rev Rep. 2021;17:952-967
22	8.	Loiola RA, Garcia-Gabilondo M, Grayston A, Bugno P, Kowalska A,
23		Duban-Deweer S, et al. Secretome of endothelial progenitor cells from stroke
24		patients promotes endothelial barrier tightness and protects against
25		hypoxia-induced vascular leakage. Stem Cell Res Ther. 2021;12

1	9.	Wang T, Fang X, Yin ZS. Endothelial progenitor cell-conditioned medium
2		promotes angiogenesis and is neuroprotective after spinal cord injury. Neural
3		Regen Res. 2018;13:887-895
4	10.	Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, et al.
5		Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by
6		vascular endothelial growth factor. Brain Pathol. 2004;14:237-248
7	11.	Maki T, Morancho A, Martinez-San Segundo P, Hayakawa K, Takase H, Liang
8		AC, et al. Endothelial progenitor cell secretome and oligovascular repair in a
9		mouse model of prolonged cerebral hypoperfusion. Stroke. 2018;49:1003-1010
10	12.	Rosell A, Morancho A, Navarro-Sobrino M, Martinez-Saez E,
11		Hernandez-Guillamon M, Lope-Piedrafita S, et al. Factors secreted by endothelial
12		progenitor cells enhance neurorepair responses after cerebral ischemia in mice.
13		<i>Plos One</i> . 2013;8
14	13.	Xing Z, Zhao C, Liu HF, Fan YB. Endothelial progenitor cell-derived
15		extracellular vesicles: A novel candidate for regenerative medicine and disease
16		treatment. Adv Healthc Mater. 2020;9
17	14.	Kong L, Wang Y, Wang H, Pan Q, Zuo R, Bai S, et al. Conditioned media from
18		endothelial progenitor cells cultured in simulated microgravity promote
19		angiogenesis and bone fracture healing. Stem Cell Res Ther. 2021;12:47
20	15.	Zhou N, Wang L, Fu P, Cui Z, Ge Y, Jiang F, et al. Conditioned
21		medium-preconditioned EPCs enhanced the ability in oligovascular repair in
22		cerebral ischemia neonatal rats. Stem Cell Res Ther. 2021;12:118
23	16.	Wang KC, Yang LY, Lee JE, Wu V, Chen TF, Hsieh ST, et al. Combination of
24		indirect revascularization and endothelial progenitor cell transplantation
25		improved cerebral perfusion and ameliorated tauopathy in a rat model of bilateral
26		ica ligation. <i>Stem Cell Res Ther</i> . 2022;13:516

1	17.	Kanzler I, Tuchscheerer N, Steffens G, Simsekyilmaz S, Konschalla S, Kroh A, et
2		al. Differential roles of angiogenic chemokines in endothelial progenitor
3		cell-induced angiogenesis. Basic Res Cardiol. 2013;108
4	18.	Ohta S, Misawa A, Fukaya R, Inoue S, Kanemura Y, Okano H, et al. Macrophage
5		migration inhibitory factor (MIF) promotes cell survival and proliferation of
6		neural stem/progenitor cells. J Cell Sci. 2012;125:3210-3220
7	19.	Song SS, Xiao ZP, Dekker FJ, Poelarends GJ, Melgert BN. Macrophage
8		migration inhibitory factor family proteins are multitasking cytokines in tissue
9		injury. Cell Mol Life Sci. 2022;79
10	20.	Welford SM, Bedogni B, Gradin K, Poellinger L, Powell MB, Giaccia AJ. HIF1
11		alpha delays premature senescence through the activation of MIF. Gene Dev.
12		2006;20:3366-3371
13	21.	De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood
14		flow is altered in patients with sepsis. Am J Resp Crit Care. 2002;166:98-104
15	22.	Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of
16		memory in rats .1. Behavioral-data. Behav Brain Res. 1988;31:47-59
17	23.	Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration
18		inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and
19		phosphatidylinositol kinase. Circ Res. 2003;93:321-329
20	24.	Kang I, Bucala R. The immunobiology of mif: Function, genetics and prospects
21		for precision medicine. Nat Rev Rheumatol. 2019;15:427-437
22	25.	Musi N, Valentine JM, Sickora KR, Baeuerle E, Thompson CS, Shen Q, et al. Tau
23		protein aggregation is associated with cellular senescence in the brain. Aging Cell.
24		2018;17
25	26.	Xia WZ, Hou M. Macrophage migration inhibitory factor rescues mesenchymal
26		stem cells from doxorubicin-induced senescence though the PI3K-AKT signaling

1	pathway. Int J Mol Med. 2018;41:1127-1137	/
---	---	---

- 2 27. Balistreri CR, Buffa S, Pisano C, Lio D, Ruvolo G, Mazzesi G. Are endothelial
  3 progenitor cells the real solution for cardiovascular diseases? Focus on
  4 controversies and perspectives. *Biomed Res Int.* 2015;2015
- 5 28. Schuh A, Liehn EA, Sasse A, Hristov M, Sobota R, Kelm M, et al.
  6 Transplantation of endothelial progenitor cells improves neovascularization and
  7 left ventricular function after myocardial infarction in a rat model. *Basic Res*8 *Cardiol.* 2008;103:69-77
- 9 29. Herberts CA, Kwa MSG, Hermsen HPH. Risk factors in the development of stem
  10 cell therapy. *J Transl Med*. 2011;9
- 30. Li YF, Ren LN, Guo G, Cannella LA, Chernaya V, Samuel S, et al. Endothelial
   progenitor cells in ischemic stroke: An exploration from hypothesis to therapy. J
   *Hematol Oncol.* 2015;8
- 14 31. Wang J, Chen S, Bihl J. Exosome-mediated transfer of ACE2
  15 (angiotensin-converting enzyme 2) from endothelial progenitor cells promotes
  16 survival and function of endothelial cell. *Oxid Med Cell Longev*.
  17 2020;2020:4213541
- 32. Wang JJ, Chen SZ, Zhang WF, Chen YF, Bihl JC. Exosomes from
   miRNA-126-modified endothelial progenitor cells alleviate brain injury and
   promote functional recovery after stroke. *Cns Neurosci Ther*. 2020;26:1255-1265
- 33. Chatterjee M, Borst O, Walker B, Fotinos A, Vogel S, Seizer P, et al. Macrophage
   migration inhibitory factor limits activation-induced apoptosis of platelets via
   CXCR7-dependent AKT signaling. *Circ Res.* 2014;115:939-+
- 34. Kim JA, Kim YY, Lee SH, Jung C, Kim MH, Kim DY. Neuroprotective effect of
  macrophage migration inhibitory factor (MIF) in a mouse model of ischemic
  stroke. *Int J Mol Sci.* 2022;23

1	35.	Chang MC, Park CR, Rine SH, Shim WH, Kim DY. Early treadmill exercise
2		increases macrophage migration inhibitory factor expression after cerebral
3		ischemia/reperfusion. Neural Regen Res. 2019;14:1230-1236
4	36.	Zhang S, Zis O, Ly PTT, Wu YL, Zhang ST, Zhang MM, et al. Down-regulation
5		of MIF by NF kappa B under hypoxia accelerated neuronal loss during stroke.
6		Faseb J. 2014;28:4394-4407
7	37.	Stoppe C, Averdunk L, Goetzenich A, Soppert J, Marlier A, Kraemer S, et al. The
8		protective role of macrophage migration inhibitory factor in acute kidney injury
9		after cardiac surgery. Sci Transl Med. 2018;10
10	38.	Amin MA, Kumar P, Connors MA, Volpert OV, Koch AE. Migration inhibitory
11		factor mediates angiogenesis via phosphatidylinositol 3-kinase (PI3K) and
12		mitogen activated protein kinase (P38). Faseb J. 2002;16:A89-A89
13	39.	Cui JJ, Zhang FY, Wang YS, Liu JJ, Ming X, Hou JB, et al. Macrophage
14		migration inhibitory factor promotes cardiac stem cell proliferation and
15		endothelial differentiation through the activation of the PI3K/AKT/mTOR and
16		AMPK pathways. Int J Mol Med. 2016;37:1299-1309
17	40.	Munaut C, Boniver J, Foidart JM, Deprez M. Macrophage migration inhibitory
18		factor (MIF) expression in human glioblastomas correlates with vascular
19		endothelial growth factor (VEGF) expression. Neuropath Appl Neuro.
20		2002;28:452-460
21	41.	Wang CW, Ma PJ, Wang YY, Yang M, Su LL, Wang S, et al. Serum level of
22		macrophage migration inhibitory factor predicts severity and prognosis in
23		patients with ischemic stroke. Cytokine. 2019;115:8-12
24	42.	Inacio AR, Ruscher K, Leng L, Bucala R, Deierborg T. Macrophage migration
25		inhibitory factor promotes cell death and aggravates neurologic deficits after
26		experimental stroke. J Cereb Blood Flow Metab. 2011;31:1093-1106 24

1	43.	Liu YC, Tsai YH, Tang SC, Liou HC, Kang KH, Liou HH, et al. Cytokine MIF
2		enhances blood-brain barrier permeability: Impact for therapy in ischemic stroke.
3		<i>Sci Rep-Uk.</i> 2018;8
4	44.	Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal
5		transduction initiated by binding to CD74. J Exp Med. 2003;197:1467-1476
6	45.	Palumbo S, Tsai TL, Li WJ. Macrophage migration inhibitory factor regulates
7		AKT signaling in hypoxic culture to modulate senescence of human
8		mesenchymal stem cells. Stem Cells Dev. 2014;23:852-865
9	46.	Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is
10		a noncognate ligand of CXC chemokine receptors in inflammatory and
11		atherogenic cell recruitment. Nat Med. 2007;13:587-596
12	47.	Guo X, Xu SG, Gao X, Wang J, Xue H, Chen ZH, et al. Macrophage migration
13		inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia
14		via CXCR4/AKT/EMT pathway in human glioblastoma cells. Oncotarget.
15		2017;8:80358-80372
16	48.	Gao Y, Li D, Lin JW, Thomas AM, Miao JY, Chen D, et al. Cerebral small vessel
17		disease: Pathological mechanisms and potential therapeutic targets. Front Aging
18		Neurosci. 2022;14
19	49.	Simons D, Grieb G, Hristov M, Pallua N, Weber C, Bernhagen J, et al.
20		Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor
21		and role in endothelial progenitor cell recruitment. J Cell Mol Med.
22		2011;15:668-678
23		

24

#### **Figures with Figure Legends** 1



Fig.1 EPC-CM treatment rescues the vascular impairment induced in BICAL 5 6 rat.

7 A, The artery (a) and vein (v) were observed on the brain surface by the videoscopic 8 view. The microcirculation on the cortical surface was significantly decreased in BICAL-rat. Scale bar = 50  $\mu$ m. **B**, The effects of EPC-CM after BICAL on the 9 10 cerebral microvasculature density was quantified by using a CAM1 capillary 11 anemometer. C and D, The effects of EPC-CM on the microvascular system after 12 BICAL were evaluated by regional blood flow (C) and the partial pressure of brain tissue oxygen (PbtO<sub>2</sub>) (**D**). Data was showed as the mean  $\pm$  SD, and analyzed using 13 by One-way ANOVA. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, n = 5-6 in each 14 15 experiment.

16

2

3 4

All rights reserved. No reuse allowed without permission.



# Fig2. Both EPC-CM and MIF protein promote the angiogenesis ability in OGD-treated endothelial cells

1

A, Cytokine profile in the EPC-CM was determined using Quantitative Cytokine 4 5 Quantibody Human Array 4000 (RayBiotech, Norcross, GA). B, The cell survival 6 ratio of the OGD-treated HUVEC cells with/without EPC-CM or recombinant MIF 7 treatment was detected by CCK-8 assay at OD 450nm and normalized with normoxia group. C, Representative images exhibited the tube formation in HUVEC cells with 8 9 different treatments (left panel), and the average total length of tubes was quantitatively analyzed by 5 fields randomly (right panel). **D**, Representative images 10 11 of the crystal violet staining of the HUVECs passed through the transwell membrane 12 (left panel). The migrated cell numbers were quantitatively analyzed by 6 fields randomly (right panel). (C), (D) Scale bar = 100  $\mu$ m. Data was showed as the mean  $\pm$ 13 SD, and analyzed using by One-way ANOVA \*\* p < 0.01, \*\*\* p < 0.001. 14



2 Fig 3. Both EPC-CM and MIF protein protect against the H<sub>2</sub>O<sub>2</sub>-induced 3 senescence of ECs and EPCs

4 A and B, Representative bright micrographs of SA- $\beta$ -gal staining of H<sub>2</sub>O<sub>2</sub>-treated 5 cells. Senescence of the young EPCs (A) or the HUVECs (B) (passage <10) was induced by H<sub>2</sub>O<sub>2</sub> treatment, followed with EPC-CM (20%) or recombinant MIF 6 7 protein (100 ng/ml) treatment (left panel). The senescence ratio was quantitatively 8 analyzed of the SA-β-gal positive cells normalized with DAPI staining. The data was 9 comparted with  $H_2O_2$  group (right panel). Scale bar = 100 µm. Data was showed as the mean  $\pm$  SD, and analyzed using by One-way ANOVA. \* p < 0.05, \*\* p < 0.01, \*\*\* 10 11 p < 0.001.

12





4 A, Representative images of tube formation was examined by Matrigel assay (left panel). The total tube length in five random fields was quantified by MetaMorph 5 software and showed as bar graph (right panel). Scale bar =  $100 \mu m$ . **B**, Determination 6 7 of the HUVECs passed through the transwell membrane stained with the crystal violet 8 (left panel). The migrated cell numbers were quantitative analyzed by 6 fields 9 randomly (right panel). Scale bar = 100  $\mu$ m. Data was showed as the mean  $\pm$  SD, and analyzed using by One-way ANOVA. \*\* p < 0.01, \*\*\* p < 0.001. 10



2 Fig 5. MIF is the key factor in the EPC-CM to promote vascular repair and 3 protects the motor function and cognition after BICAL.

A, The schematic representation of the experimental process. B and C, Determination 4 5 of the vascular function of BICAL-rat treated with EPC-CM or EPC-CM+MIF Ab by 6 analyzed the regional blood flow (B) or the partial pressure of brain tissue oxygen 7 (PbtO<sub>2</sub>) (C) (n=5 in each group). **D**, The effects of EPC-CM and EPC-CM+MIF Ab 8 on the motor function was evaluated by rotarod test (n=6). E, The recognition memory function in BICAL rat treated with/without EPC-CM or the EPC-CM+MIF 9 Ab was detected by NOR test. The duration of time spent exploring the novel object 10 was normalized with total time spent exploring both objects (n>5). Data was showed 11 as the mean  $\pm$  SD, and analyzed using by One-way ANOVA. \* p < 0.05, \*\* p < 0.01, 12 \*\*\* *p* < 0.001. 13

14





1

2

5 A, Determination the AKT and ERK1/2 activity upon the treatment of EPC-CM or 6 recombinant MIF protein in different time points in the EPCs. The EPCs were treated 7 with rMIF (100 ng/ml ) or EPC-CM (20%) for the indicated time and harvested the 8 cell lysates for Western blotting analysis. **B**, Detection of the AKT and ERK1/2 activity in OGD-treated cells incubated with EPC-CM, or rMIF, or rMIF+LY294002. 9

1 HUVECs (left panel) or EPCs (right panel) were incubated with/without EPC-CM 2 (20%), or rMIF (100ng/ml), or the rMIF+LY294002 (5nM) at 0.5 % O<sub>2</sub> incubator for 3 24 hrs. The cell lysates were collected to detect the AKT and ERK1/2 activity by using the Western analysis. C, Representative images of the tube formation of the 4 OGD-treated cells incubated with different chemicals (left panel). The average total 5 tube length of five random fields was quantified and showed as bar graph (right panel). 6 Scale bar =  $100 \mu m$ . **D**, Representative images of the HUVECs passed through the 7 transwell membrane stained with crystal violet (left panel). The migrated cell numbers 8 9 were quantitative analyzed by 6 random fields (right panel). Scale bar = 100  $\mu$ m. E, 10 Images of the SA-β-gal staining of H<sub>2</sub>O<sub>2</sub>-induced senescent cells treated with different chemicals in HUVEC cells. The senescence ratio was the SA-β-gal positive cells 11 normalized with the DAPI in 6 independent fields. The data wad comparted with the 12  $H_2O_2$  group (right panel). Scale bar = 100 µm, Data was showed as the mean  $\pm$  SD, 13 and analyzed using by One-way ANOVA. \*\* p < 0.01, \*\*\* p < 0.001. 14